JP2010513304A5 - - Google Patents

Download PDF

Info

Publication number
JP2010513304A5
JP2010513304A5 JP2009541584A JP2009541584A JP2010513304A5 JP 2010513304 A5 JP2010513304 A5 JP 2010513304A5 JP 2009541584 A JP2009541584 A JP 2009541584A JP 2009541584 A JP2009541584 A JP 2009541584A JP 2010513304 A5 JP2010513304 A5 JP 2010513304A5
Authority
JP
Japan
Prior art keywords
chlorophenyl
substituted
nhco
independently
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009541584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513304A (ja
JP5342450B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/087396 external-priority patent/WO2008076805A2/en
Publication of JP2010513304A publication Critical patent/JP2010513304A/ja
Publication of JP2010513304A5 publication Critical patent/JP2010513304A5/ja
Application granted granted Critical
Publication of JP5342450B2 publication Critical patent/JP5342450B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009541584A 2006-12-15 2007-12-13 第XIa因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ Expired - Fee Related JP5342450B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87011006P 2006-12-15 2006-12-15
US60/870,110 2006-12-15
PCT/US2007/087396 WO2008076805A2 (en) 2006-12-15 2007-12-13 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors

Publications (3)

Publication Number Publication Date
JP2010513304A JP2010513304A (ja) 2010-04-30
JP2010513304A5 true JP2010513304A5 (enExample) 2010-10-14
JP5342450B2 JP5342450B2 (ja) 2013-11-13

Family

ID=39414952

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009541584A Expired - Fee Related JP5342450B2 (ja) 2006-12-15 2007-12-13 第XIa因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ

Country Status (7)

Country Link
US (1) US8410155B2 (enExample)
EP (1) EP2102189B1 (enExample)
JP (1) JP5342450B2 (enExample)
CN (1) CN101605779B (enExample)
ES (1) ES2546815T3 (enExample)
NO (1) NO20092165L (enExample)
WO (1) WO2008076805A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114677A1 (en) * 2008-03-13 2009-09-17 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
EP2534152B1 (en) * 2010-02-11 2018-05-02 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
LV14606B (lv) 2011-05-17 2013-01-20 Tetra, Sia Jauns XII faktora inhibitors
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子xia抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為xia因子抑制劑之環狀p1接合劑
IN2014CN02805A (enExample) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
CN103974938B (zh) 2011-10-14 2016-11-09 百时美施贵宝公司 作为因子xia抑制剂的经取代的四氢异喹啉化合物
ES2699226T3 (es) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
GB2497806A (en) * 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
CN104136431B (zh) * 2011-12-21 2017-03-15 小野药品工业株式会社 作为凝血因子XIa抑制剂的吡啶酮和嘧啶酮衍生物
GB201209138D0 (en) 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds
SG11201500270RA (en) 2012-08-03 2015-03-30 Bristol Myers Squibb Co Dihydropyridone p1 as factor xia inhibitors
US9409908B2 (en) 2012-08-03 2016-08-09 Bristol-Myers Squibb Company Dihydropyridone p1 as factor XIa inhibitors
JP6154473B2 (ja) 2012-10-12 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 第XIa因子阻害剤の結晶形
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
US9475809B2 (en) * 2013-07-23 2016-10-25 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
TWI688564B (zh) 2014-01-31 2020-03-21 美商必治妥美雅史谷比公司 作為凝血因子xia抑制劑之具有雜環p2'基團之巨環化合物
NO2760821T3 (enExample) 2014-01-31 2018-03-10
US9944643B2 (en) 2014-02-11 2018-04-17 Merck Sharp & Dohme Corp. Factor XIa inhibitors
US9676723B2 (en) 2014-02-11 2017-06-13 Merck Sharp & Dohme Corp Factor XIa inhibitors
AU2015298491A1 (en) * 2014-02-14 2016-09-01 The University Of British Columbia Modulators of caspase-6
US20190192524A1 (en) * 2014-02-14 2019-06-27 The University Of British Columbia Modulators of Caspase-6
US9969724B2 (en) 2014-04-16 2018-05-15 Merck Sharp & Dohme Corp. Factor IXa inhibitors
EP3134408B1 (en) 2014-04-22 2020-08-12 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
US9868727B2 (en) 2014-07-28 2018-01-16 Merck Sharp & Dohme Corp. Factor XIa inhibitors
WO2016036893A1 (en) * 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
EP3231803B1 (en) 2014-12-10 2020-07-01 ONO Pharmaceutical Co., Ltd. Dihydroindolizinone derivative
ES2762987T3 (es) 2015-06-19 2020-05-26 Bristol Myers Squibb Co Macrociclos de diamida como inhibidores del factor XIA
KR102086934B1 (ko) 2015-07-29 2020-03-09 브리스톨-마이어스 스큅 컴퍼니 알킬 또는 시클로알킬 P2' 모이어티를 갖는 인자 XIa 마크로시클릭 억제제
ES2871111T3 (es) 2015-07-29 2021-10-28 Bristol Myers Squibb Co Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático
AU2016344476B2 (en) 2015-10-29 2020-08-13 Merck Sharp & Dohme Llc Factor XIa inhibitors
EP3371162B1 (en) 2015-10-29 2022-01-26 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
EP3170822A1 (en) 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
WO2018039094A1 (en) 2016-08-22 2018-03-01 Merck Sharp & Dohme Corp. Pyridine-1-oxide derivatives and their use as factor xia inhibitors
WO2020037094A1 (en) 2018-08-16 2020-02-20 Innate Tumor Immunity, Inc. Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
CN112028877B (zh) * 2019-06-04 2021-11-26 江西济民可信集团有限公司 烷氧吡啶酮化合物及其制备方法和用途
KR20240099477A (ko) * 2021-11-15 2024-06-28 가부시키가이샤 시마쓰세사쿠쇼 유전자 다형을 이용한 판정 방법
EP4212531A1 (en) 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
AU2024249981A1 (en) 2023-04-06 2025-10-16 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
EP1382607B1 (en) * 1998-12-31 2009-08-19 Ipsen Pharma Prenyl transferase inhibitors
CA2383008A1 (en) 1999-06-14 2000-12-21 Amanda Jane Lyons Compounds
US20040132788A1 (en) * 1999-10-11 2004-07-08 Chabrier De Lassauniere Pierre-Etienne Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
DE10102322A1 (de) * 2001-01-19 2002-07-25 Merck Patent Gmbh Phenylderivate
CN110894196A (zh) 2001-09-21 2020-03-20 百时美-施贵宝控股爱尔兰无限公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
JPWO2003089431A1 (ja) * 2002-04-19 2005-08-25 住友製薬株式会社 新規なカルバペネム化合物
DE10238002A1 (de) * 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
WO2004087679A1 (en) 2003-04-01 2004-10-14 Aponetics Ag 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
CA2559866A1 (en) 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
CN101080392B (zh) * 2004-12-16 2010-05-05 霍夫曼-拉罗奇有限公司 作为抗肥胖药剂的哌嗪基吡啶衍生物
CN101137412B (zh) 2005-01-13 2012-11-07 布里斯托尔-迈尔斯·斯奎布公司 用作凝血因子XIa抑制剂的取代的二芳基化合物
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
US7626039B2 (en) * 2005-12-14 2009-12-01 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors
JP2009519966A (ja) * 2005-12-14 2009-05-21 ブリストル−マイヤーズ スクイブ カンパニー セリンプロテアーゼ阻害剤として有用な6員ヘテロ環
WO2007070816A2 (en) * 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Thiophene derivatives as factor xia inhibitors

Similar Documents

Publication Publication Date Title
JP2010513304A5 (enExample)
JP2009519967A5 (enExample)
JP2010529991A5 (enExample)
JP4310109B2 (ja) ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
CN106061480B (zh) 治疗性抑制性化合物
CN100358888C (zh) 作为因子Xa抑制剂的新的胍模拟物
RU2329261C2 (ru) Новое 2-гетероарил-замещенное производное бензимидазола
JP2021119196A5 (enExample)
EP2207773B1 (en) Heterocyclic compound and pharmaceutical composition thereof
HRP20170019T1 (hr) Novi pirol-inhibitori od reduktaze s-nitrozoglutationa kao terapeutska sredstva
JP2006500348A5 (enExample)
MX2013001363A (es) N- ((6-amino-piridin-3-il)-metil) -heteroaril-carboxamidas como inhibidoras de calicreina de plasma.
WO2006071940A2 (en) Enzyme modulators and treatments
WO2001068585A1 (en) Novel amide compounds
WO2007070826B1 (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
JP2005507889A (ja) 第Xa因子阻害剤としてのラクタム含有化合物およびその誘導体
KR20150002863A (ko) 헤지호그 신호전달에 대한 피리딜 억제제
JP2002523511A5 (enExample)
JP2020526547A5 (enExample)
JP2001524116A (ja) 5ht1a、5ht1bおよび5ht1d受容体アンタゴニスト活性を合わせ持つインドール誘導体
JP7084946B2 (ja) 置換窒素含有化合物
TW201302730A (zh) 吡唑化合物
TWI794844B (zh) 包含經由鏈接子連接之2或更多芳基或雜芳基的新穎羰基亞肼基二氰化物化合物及其用途
WO2006049304A1 (ja) アリールオキシ置換ベンズイミダゾール誘導体
JP2020512401A5 (enExample)